These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 31645711)

  • 1. The pro-tumorigenic host response to cancer therapies.
    Shaked Y
    Nat Rev Cancer; 2019 Dec; 19(12):667-685. PubMed ID: 31645711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multifaceted role of exosomes in cancer progression: diagnostic and therapeutic implications [corrected].
    Sundararajan V; Sarkar FH; Ramasamy TS
    Cell Oncol (Dordr); 2018 Jun; 41(3):223-252. PubMed ID: 29667069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour macrophages as potential targets of bisphosphonates.
    Rogers TL; Holen I
    J Transl Med; 2011 Oct; 9():177. PubMed ID: 22005011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment after progression in the era of immunotherapy.
    Billan S; Kaidar-Person O; Gil Z
    Lancet Oncol; 2020 Oct; 21(10):e463-e476. PubMed ID: 33002442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer.
    Korentzelos D; Clark AM; Wells A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33022920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biology and function of fibroblasts in cancer.
    Kalluri R
    Nat Rev Cancer; 2016 Aug; 16(9):582-98. PubMed ID: 27550820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host effects contributing to cancer therapy resistance.
    Katz OB; Shaked Y
    Drug Resist Updat; 2015 Mar; 19():33-42. PubMed ID: 25575621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor microenvironment and cancer therapy resistance.
    Sun Y
    Cancer Lett; 2016 Sep; 380(1):205-15. PubMed ID: 26272180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hallmarks of response to immune checkpoint blockade.
    Cogdill AP; Andrews MC; Wargo JA
    Br J Cancer; 2017 Jun; 117(1):1-7. PubMed ID: 28524159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive cells in tumor immune escape and metastasis.
    Liu Y; Cao X
    J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor dormancy and cancer stem cells: two sides of the same coin?
    Kleffel S; Schatton T
    Adv Exp Med Biol; 2013; 734():145-79. PubMed ID: 23143979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour Cell Secretome in Chemoresistance and Tumour Recurrence.
    Madden EC; Gorman AM; Logue SE; Samali A
    Trends Cancer; 2020 Jun; 6(6):489-505. PubMed ID: 32460003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The host support niche as a control point for tumor dormancy: implications for tumor development and beyond.
    Hahnfeldt P
    Adv Exp Med Biol; 2013; 734():19-35. PubMed ID: 23143973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance and therapeutic implications of endothelial progenitor cells in angiogenic-mediated tumour metastasis.
    Flamini V; Jiang WG; Lane J; Cui YX
    Crit Rev Oncol Hematol; 2016 Apr; 100():177-89. PubMed ID: 26917455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
    Flower KJ; Ghaem-Maghami S; Brown R
    Curr Cancer Drug Targets; 2018; 18(1):5-15. PubMed ID: 28176650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.
    Clara JA; Monge C; Yang Y; Takebe N
    Nat Rev Clin Oncol; 2020 Apr; 17(4):204-232. PubMed ID: 31792354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Models, mechanisms and clinical evidence for cancer dormancy.
    Aguirre-Ghiso JA
    Nat Rev Cancer; 2007 Nov; 7(11):834-46. PubMed ID: 17957189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives.
    Zahan T; Das PK; Akter SF; Habib R; Rahman MH; Karim MR; Islam F
    Anticancer Agents Med Chem; 2020; 20(18):2190-2206. PubMed ID: 32748758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.